Literature DB >> 2729950

Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.

M Venditti1, P Baiocchi, C Santini, C Brandimarte, P Serra, G Gentile, C Girmenia, P Martino.   

Abstract

Sixty-three consecutive streptococcal blood isolates from neutropenic patients, represented mainly by viridans group streptococci, were evaluated in vitro for antibiotic susceptibility. Of these isolates, 79.3% were highly susceptible to penicillin (MIC, less than or equal to 0.12 microgram/ml). Overall, imipenem was the most active agent, followed by teicoplanin and vancomycin. All other agents showed decreased activity against streptococcal isolates that were not highly susceptible to penicillin.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2729950      PMCID： PMC172484          DOI： 10.1128/AAC.33.4.580

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Adult respiratory distress syndrome in patients with severe neutropenia.

Authors:  F P Ognibene; S E Martin; M M Parker; T Schlesinger; P Roach; C Burch; J H Shelhamer; J E Parrillo
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

2.  Streptococcal sepsis in bone marrow transplant patients.

Authors:  J Henslee; B Bostrom; D Weisdorf; N Ramsay; P McGlave; J Kersey
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

3.  Speciation of the "viridans" streptococci.

Authors:  M Sands; H M Sommers; M B Rubin
Journal:  Am J Clin Pathol       Date:  1982-07       Impact factor: 2.493

4.  Antimicrobial susceptibilities of species of viridans streptococci.

Authors:  A M Bourgault; W R Wilson; J A Washington
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

5.  Neutropenia, fever, and infection.

Authors:  A E Brown
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

6.  Viridans streptococci septicemia in cancer patients: a clinical study.

Authors:  F Menichetti; A Del Favero; R Guerciolini; M Tonato; R F Frongillo; F Roila; S Pauluzzi
Journal:  Eur J Epidemiol       Date:  1987-09       Impact factor: 8.082

7.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Klin Wochenschr       Date:  1987-08-17

8.  Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia.

Authors:  J Cohen; J P Donnelly; A M Worsley; D Catovsky; J M Goldman; D A Galton
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

9.  Evaluation of the Rapid Strep system for the identification of clinical isolates of Streptococcus species.

Authors:  R R Facklam; D L Rhoden; P B Smith
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948
  9 in total
  26 in total

1.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci.

Authors:  S J Rosser; M J Alfa; S Hoban; J Kennedy; G K Harding
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

4.  Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis.

Authors:  W Kern; K Linzmeier; E Kurrle
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

5.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Authors:  I González; M Georgiou; F Alcaide; D Balas; J Liñares; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Chromosomally mediated high-level gentamicin resistance in Streptococcus mitis.

Authors:  A Kaufhold; E Potgieter
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

10.  4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin.

Authors:  M Venditti; V Gelfusa; P Serra; C Brandimarte; A Micozzi; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.